Veru, founded as an oncology biopharmaceutical company, aims to innovate novel treatments for prostate and breast cancers. The company's mission is to develop and commercialize high-quality therapies that address significant medical needs, including weight loss and viral-related ARDS. Veru's core products include a selective androgen receptor modulator (SARM) designed to mitigate muscle loss in patients undergoing weight loss therapy with GLP- drugs.
Notable individuals affiliated with Veru include its leadership team, composed of experienced professionals in the biopharmaceutical industry. The company has garnered investment from key stakeholders committed to advancing oncology treatments. Veru's significant achievements include the development of promising therapies that have the potential to transform cancer treatment paradigms. Its impact is marked by a commitment to improving patient outcomes in oncology and related fields.
